Boehringer Ingelheim's oral hepatitis C protease inhibitor and polymerase inhibitor combination shows rapid viral response without use of pegylated interferon
BOSTON, MA and INGELHEIM, Germany, 30 October 2010 β Boehringer Ingelheim announced results from a Phase Ib study, SOUND-C1, that showed the combination of two oral hepatitis C virus (HCV) compounds, the protease inhibitor BI 201335 and the polymerase inhibitor BI 207127, with ribavirin reduced viral load to the lower limit of quantifiable levels in HCV treatment-naΓ―ve patients. The regimen did not include interferon through the first 28 days of treatment. These data are being presented at the American Association for the Study of Liver Diseases (AASLD) 2010 Liver Meeting in Boston, MA.